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Abstract
Triple Negative Breast Cancer (TNBC), an aggressive form of breast cancer, has abnormal
therapeutic results; leading to the need for unique treatment methods. Currently TNBC has no
specific targeted therapy and has limited response to other chemotherapeutics. Plant extracts
have shown to be useful as chemopreventive agents due to their disruption of pro-survival and
proliferative mechanisms on cancer cells. Rosehip extracts have shown anti-proliferative activity
against cancer cells in vitro. We hypothesized that rosehip extracts will inhibit cell proliferation
in triple negative breast cancer cell lines at varying concentrations. Therefore, this study was
designed to investigate the effect of rosehip extracts as anti-proliferative agents in AfricanAmerican TNBC cell lines (HCC1806 and MB157), luminal breast cancer cell lines (HCC70 and
HCC1500), and a primary breast cell line (AG11132) as a model for non-cancerous tissues. To
determine the inhibitory role of rosehip extracts in cell proliferation, MTT assays were
conducted, following treatment with varying concentrations of rosehip extracts (1mg/ml,
250ug/ml, 25ug/ml, and 25ng/ml) for 48 hours. The data suggests that rosehip extracts, can
significantly decrease cell proliferation. Western blot analysis was used to investigate which
signaling pathway rosehip extracts were affecting. Western blot analysis suggests that rosehip
extracts are inhibiting p70 S6 kinase phosphorylation and its ability to act as a kinase for S6
ribosomal protein. Preliminary data suggests that Rosehip Methanol extracts may have a
synergistic effect with Doxorubicin, a known chemotherapeutic, in cell lines lacking the
progesterone receptor. Overall, rosehip extracts decrease cell proliferation in African-American
breast cancer cell lines, by decreasing phosphorylation along the PI3K signaling pathway.
Rosehip extracts may have the potential to serve as a neoadjuvant therapeutic in the
chemotherapeutic realm.
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CHAPTER 1
Introduction
The public health and social science sector examine diseases to identify if there are
indications of a difference in environment, access to, utilization of and quality of care. The
disproportionate burden of disease, known as health disparities, display a health outcome which
deserves attention (Chu, Miller, & Springfield, 2007). Breast cancer is the most frequently
diagnosed cancer in women. While Caucasian women are more likely to be diagnosed with
breast cancer, African-American women are more likely to die from the disease (Carey et al.,
2006). This health disparity has become the leading cause of cancer death among women in
economically developing countries (Jemal et al., 2011). Varying risk factors play a role in who
becomes diagnosed with breast cancer. Race and ethnicity appear to play a large role in
determining if an individual will develop breast cancer. In comparison to other ethnic groups,
Caucasian women and African-American women have higher incidence rates. While Caucasian
women are more likely to develop breast cancer, African-American women are more likely to
die from the disease. African-American women are also more likely to be diagnosed before the
age of 40 (Carey et al., 2006). In conjunction with developing the disease at such an early age,
African-American women are more likely to be diagnosed with aggressive late stage tumors.
Triple negative breast cancer (TNBC) is characterized by cells that lack the estrogen and
progesterone receptors and lacks an overexpression of human epidermal receptor 2 (HER-2)
(Dawood, 2010). The absence of these three vital hormone receptors causes TNBC to have
unique therapeutic results leading to the need for unique treatment methods. These receptors are
expressed in normal breast tissue and other forms of breast cancer. Each receptor plays a role in
the normal development of breast tissue. The HER-2 surface protein participates in signal
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transduction pathways that aid in differentiation and growth. This subtype of breast cancer
currently has no specific targeted therapy and there is a large amount of cases in premenopausal
women as well as African-American women.
The reasons associated with breast cancer disparity are not entirely understood. The
progression of breast cancer is believed to be a multistep process. This process includes the
activation and inactivation of several different genes, such as Her2/neu (Belguise, Kersual,
Galtier, & Chalbos, 2005). Her2/neu overexpression plays a role in the aggressiveness of breast
cancer. The mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)
are two major pathways involved in proliferation and survivalWhen this gene is overexpressed,
the MAPK and PI3K cell signaling pathways are stimulated (Hynes & MacDonald, 2009). The
increased activation of genes involved in cell proliferation, differentiation and other biological
process can be due to improper regulation and activation of transcription factors, such as the
activator-factor 1(AP-1) (Young & Colburn, 2006). AP-1 is plays a role in cell proliferation
through activation of the MAPK pathway. This transcription factor is linked to transformation
when there are elevated levels in the cell (Young & Colburn, 2006). The discovery that mitogeninduced metabolic processes may be regulated by serial phosphorylation and decreasing
phosphorylation events has been the attention of signal transduction studies for decades (Pullen
& Thomas, 1997). This pathway is responsible for cellular processes such as cell proliferation,
growth, apoptosis, and cytoskeletal rearrangement (Chang H Song, 2010). Components of the
phosphatidylinositol 3-kinase signaling are deregulated in different human cancers. One
component that is deregulated within the PI3K pathway is the p70 S6 kinase. The activity of p70
S6 kinase is controlled by multiple phosphorylation events located within the catalytic, linker
and pseudosubstrate domains. This mitogen is required for cell growth and G1 cell cycle
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progression (Pullen & Thomas, 1997). The intracellular catalytic domain of the HER-2 receptor
can be phosphorylated by the formation of homodimeric and heterodimeric kinase activecomplexes. This then leads to activation of signaling pathways that promote proliferation or
survival of breast cancer cells (Chang H Song, 2010). . Mitogens within the MEK/ERK signaling
pathway function by transmitting signals from receptors to regulate gene expression and can also
play a role in the prevention of apoptosis. This pathway interacts with the PI3K pathway to
regulate growth in forms of tumorigenesis (McCubrey et al., 2006). AKT, p70 S6 kinase, and
ribosomal protein S6 are among the most important of the downstream molecules found in
these pathways (Chang H Song, 2010). Previously it was shown that rosehip extracts diminish
AKT and MAPK signaling mechanisms in human brain tumor cell line (Cagle et al., 2012).
However, the effect of rosehip extracts on these mitogens has yet to be studied in breast cancer
cell lines and can show to be useful in finding a potential alternative treatment method for
TNBC.
Studies have shown natural products, such as plants, can have a chemopreventive effect
on cancer progression. Epidemiological studies have suggested that specific dietary
consumption patterns are associated with increased risks of developing cancer at several sites
(Tumbas et al., 2011). Antioxidants are capable of scavenging free radicals, which can oxidize
major biological macromolecules in cells and tissues (Wang, Meckling, Marcone, Kakuda, &
Tsao, 2011). The concept that consumption of antioxidant rich foods may prevent cancer or
improve treatment has been supported by some studies (Gao, Björk, Trajkovski, & Uggla, 2000).
The studies mentioned above indicate that vitamins and certain phytochemical antioxidants
including flavonoids and carotenoids are effective against proliferation of human colorectal,
breast and stomach cancer cells (Wang et al., 2011). Plant extracts have been used as
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chemopreventive agents due to their mechanistic actions on cancer cells (Amin, Kucuk, Khuri, &
Shin, 2009). Rosehip fruits have shown potent anti-proliferative activity against colon, breast,
and cervical cancer cells in vitro. Rosehips are high in vitamin C (Tumbas et al., 2011) causing
this pseudo fruit to be rich in ascorbic acid, phenolic components, and carotenoids (Chrubasik,
Roufogalis, Müller-Ladner, & Chrubasik, 2008). These high antioxidant contents cause rosehips
to have high antioxidant activities. Studies have shown rosehips are useful in treating arthritis
due to its anti-inflammatory and antioxidant effects (Andersson, Berger, Hogberg, LandinOlsson, & Holm, 2011). These dietary antioxidants may contribute to the protection of
biologically important cellular components. Antioxidants function by reacting with free oxygen
radicals and action as reducing agents to induce production of anti-oxidative enzymes. This
contributes to the inhibitory capacity against cell proliferation caused by these antioxidants (Su
et al., 2007). Studies have shown that the Vitamin C and flavonoids found in rosehips are
responsible for the antioxidant activity associated with it (Wang et al., 2011). However, it is the
polyphenols found within this plant that is responsible for the anti-proliferative activity (Wang et
al., 2011). Crude rosehip extracts inhibited cell proliferation activity without inducing apoptosis
in glioblastomas in vitro (Cagle et al., 2012). To our knowledge, the anti-proliferative effects on
cell proliferation in African-American triple negative breast cancer have not yet been tested.
The objective of the present study is to determine the effects of crude rosehip extracts on
cell proliferation and cell migration in triple negative breast cancer cell lines, and to identify
signaling pathways responsible for those effects. We hypothesized that rosehip extracts inhibit
cell proliferation in triple negative breast cancer cell lines at varying concentration levels by
blocking the AKT and Mek/Erk1/2 signaling pathways. Within this study, three objectives were
used to determine the role of rosehip extracts in African-American TNBC cell lines and luminal
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breast cancer cell lines: 1) determine the effect of rosehip extracts on cell proliferation in
African-American breast cancer cell lines (HCC70, HCC1500, HCC1806 and MB157); 2) to
identify the signaling pathways responsible for mediating rosehip extract effects on cell
proliferation in African-American breast cancer cell lines; 3) Examine whether the efficacy of
Doxorubicin, a known breast cancer chemotherapeutic, is increased when cells are pre-treated
with rosehip extracts. Due to the therapeutic challenges that triple negative breast cancer patients
face this study can lead to new and innovative therapeutic options. Although the usefulness of
rosehip extracts in breast cancer cell studies remains unknown, exploring the functional role of
these extracts can be helpful in discovering potential clinical uses. The research presented here is
thus significant, because it will lead to a better understanding of novel mechanisms of rosehip
extracts and how they can effect cell proliferation in triple negative breast cancer cell lines. This
research gives insight to rosehip extracts serving as a homeopathic treatment.
.
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CHAPTER 2
Literature Review
2.1 Breast Cancer
Breast cancer is defined as a malignancy that forms in tissues of the breast usually within
the ducts, which are the tubes that carry milk to the nipple. It can also affect the lobules, which
are the glands that make milk. Breast cancer can either be invasive or noninvasive. Invasive
forms of the cancer spread from the milk duct or lobule to other tissues of the breast. Breast
cancer has the ability to affect both men and women; however, men being diagnosed with breast
cancer are a rarity. The causality of breast cancer is still poorly understood; however there have
been links to lifestyle choices or habits to its increased risk (Reddy, Odhav, & Bhoola, 2003).
Risk factors may also include age, genetics, exposure to radiation, and family history of cancer
(Yang et al., 2007). Women with longer menstrual histories are also at a greatest risk. Studies
have shown that women that start their menstrual cycles early in life or end later in life are at a
greater risk of being diagnosed with breast cancer (Ursin et al., 2005).
Breast cancer, a heterogeneous disease, is composed of various recognized biological
subtypes (Carey et al., 2006). The classification of these subtypes of the disease is able to assist
in prognostication and targeting of treatment. The classification of subtypes is determined by the
presence of certain identifiable markers. Estrogen positive tumors fall in the category of being
either luminal A or luminal B, while estrogen negative tumors may be basal-like or human
epidermal growth factor receptor 2 (HER-2) positive/estrogen receptor negative (Carey et al.,
2006). Luminal A tumors are estrogen receptor and progesterone receptor positive, HER-2
negative, and express low levels of Ki-67. Luminal B tumors have similar characteristics to the
luminal A tumors; however, these tumors express high levels of Ki-67 and can be either HER-2
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negative or positive. The genes associated with this subtype of tumors indicate higher
proliferation rates in comparison to luminal A tumors (Goldhirsch et al., 2011). Basal-like
tumors show low expressions of HER-2 and the estrogen receptor. This subtype has high
expression of genes which are characteristic of the basal epithelial cell layers. 80% of triple
negative tumors overlap with the basal-like subtype, even though triple negative tumors do
express some unique characteristics of its own (Goldhirsch et al., 2011).
Breast cancer diagnosis is a critical prelude to treatment options in patients. Tools such as
clinical breast exams and mammography are used to diagnosis women with breast cancer. These
diagnostic methods are part of early detection screening. There are several benefits associated
with early detection screening such as ability to detect the disease at an early age. By detecting
the disease at an early age, patients are less likely to have aggressive forms of the disease. This is
beneficial to patients allowing them to have a wider range of treatment options such as less
aggressive surgery and adjuvant therapy (Dunn, Agurs-Collins, Browne, Lubet, & Johnson,
2010).
There are several factors which play a role in a patient’s chances of survival, such as
stage at diagnosis, age, socioeconomic factors, obesity, and tumor characteristics. The five year
survival rate is lower in women who have a more advanced stage of the disease when diagnosed.
Women who are diagnosed before age forty have a lower survival rate in comparison to women
diagnosed at forty or older (Newman et al., 2006). Several studies have shown a poorer
prognosis for women diagnosed at a young age (≤35). Although these women are in the
minority, they typically have larger more aggressive tumors (El Saghir et al., 2006). Although
the rate of survival has increased over the years, there is still a very large racial gap between
Caucasian women and African-American women. Studies have shown poverty and a lack of
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health insurance are associated with a lower survival rate (Newman et al., 2006). Obese patients
are 30% more likely to die from breast cancer in comparison to those who maintain a healthy
weight. This is shown in several studies which suggest that exercise throughout treatment can
improve the outcome of the disease (Dunn et al., 2010). Patients with estrogen receptor positive
and progesterone receptor positive tumors have the most favorable prognosis. The presence of
the estrogen and progesterone receptors allows the patients to have favorable responses to
hormonal therapies. However, patients with triple negative tumors or tumors with HER-2
overexpression have a less favorable prognosis (Dunnwald, Rossing, & Li, 2007).
It is not completely understood why women under the age of 35 have poorer prognosis;
however, there are several studies that have tried to solve the puzzle associated with this
phenomenon. Women diagnosed before the age of 40, typically have tumors that are less well
differentiated, have a higher proliferating fraction as defined by the amount of Ki-67 present, and
are more likely to have lymph node invasion (Shannon & Smith, 2003). Other studies have
shown women under the age of 35 have more advanced stages of the disease at diagnosis which
contributes to a poorer 5-year survival rate (Chung, Chang, Bland, & Wanebo, 1998). A study
conducted by Colleoni and colleagues, sought to evaluate the pathological features and staging of
breast cancer in premenopausal women recently diagnosed with invasive breast cancer and
referred to surgery. Researchers concluded that women under 35 were more like to have tumors
classified as lacking the estrogen and progesterone receptors. These tumors are also had a high
Ki-67 rate suggesting that the tumor is highly proliferative. These patients’ tumors were also
high invasive (Colleoni et al., 2002).
Once diagnosed patients and their physicians decide what is the optimal treatment based
on the stage and biological characteristics of the tumor. Factors such as age, preference, risk and
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benefits are taken into account before a decision is made. There are various different treatment
options. Forms of treatment are radiation, hormone or target therapy, chemotherapy, and surgery.
Systemic treatments (hormone therapy and chemotherapy) operate by entering the bloodstream
and destroying or controlling the cancer in the body. Specifically, chemotherapy kills circulating
cancer cells. Chemotherapeutics offer a greater response when combined with other drugs such
as Doxorubicin, an anthracycline antibiotic. (Kaur, Saini, Peer, & Singh, 2010). Doxorubicin
slows or stops the growth of cancer cells by preventing DNA replication and inhibiting protein
synthesis. This anthracycline is commonly used in combination with Paclitaxel to treat
aggressive breast cancers (Du et al., 2010). The poor prognosis of triple negative breast cancer is
due to the lack of response to chemotherapeutics, in comparison to other forms of breast cancer.
This is also attributed to the relapse that occurs if the tumor is not completely removed initially
(Kaur et al., 2010).
2.2 Triple Negative Breast Cancer
Triple-Negative Breast Cancer (TNBC) is a specific breast cancer phenotype; which
lacks the estrogen receptor (ER), the progesterone receptor (PR), and the human epidermal
growth factor-2 receptor (HER-2) (Dawood, 2010). These receptors are expressed in normal
breast tissue and other forms of breast cancer. Each receptor plays a role in the normal
development of breast tissue. Estrogen plays a role in female development, and thus is
responsible for regulation of breast growth and the menstrual cycle. During pregnancy, estrogen
works as a regulator for progesterone production. Progesterone is secreted by the ovaries and
works in conjunction with estrogen to regulate breast growth and the menstrual cycle. This
hormone prevents the uterus from contracting prematurely during pregnancy. HER-2 is a surface
protein. This protein participates in signal transduction pathways that aid in differentiation and

12
growth. The lack of these receptors contributes to the aggressiveness of triple negative breast
cancer (Wang et al., 2011). The absence of these receptors also plays a role in the therapeutic
challenges that are associated with triple negative breast cancer.
TNBC represents 15% of all breast cancers (Conte & Guarneri, 2009). Triple negative
breast cancer prognosis is different from the other subtypes of the disease. Patients diagnosed
with triple negative are less likely to reach the five year survival mark. The five year survival
rate is based on the stage of the disease at diagnosis. Earlier stages of diseases have an 84%
chance of survival during the first five years of disease, while later stages only have an 18%
chance (Fallowfield, 2004). Triple negative breast cancer patients are also more likely to suffer
from metastatic recurrence within the first three years of treatment (Dent et al., 2007). Other
characteristics associated with the poor prognosis of triple negative breast cancer are: large
tumor sizes, poor tubule formation, high tumor grades, high mitotic index, and necrosis
(Yamamoto & Iwase, 2010).
Triple negative breast cancers are characterized by aggressive clinical features such as
onset at an early age (≤35), larger tumor sizes, and higher grades of tumors. Canadian scientists,
Dent and colleagues evaluated prognosis in over 1,500 women. The study questioned the
likelihood of distant recurrence and death among women with triple-negative breast cancer in
comparison to patients with non-triple negative forms of breast cancer. The results indicated that
women with triple negative breast cancer were more likely to develop recurrence following
treatment within the first three years. These patients were also more like to develop brain
metastasis (Dent et al., 2007). It is estimated that 15% of all patients diagnosed with triple
negative breast cancer will develop brain metastasis. Once brain metastasis occurs patients have
an average survival time of six months (Boogerd, Vos, Hart, & Baris, 1993). While triple
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negative breast cancer is not resistant to current chemotherapeutics it is not as responsive to
treatment as other subtypes of breast cancer. Some suggested approaches to future treatments
include use of DNA-damaging agents, targeting receptors such as the epidermal growth factor
receptor (EGFR) and the vascular endothelial growth factor (VEGF), and poly-ADP ribose
polymerase inhibitors (C. Anders & Carey, 2008).
2.3 African-American Women and Breast Cancer
Breast Cancer is a major health disparity among the African-American community
behind cardiovascular disease. It is the second leading cause of death in African-American
women. This community is more likely to be diagnosed with aggressive forms of breast cancer in
comparison to the Caucasian community. The triple negative tumors in African-American
women are more likely to have a higher mitotic activity and be poorly differentiated (Jones et al.,
2004). A study conducted by Chen and associates, examined the histological characteristics of
tumors from blacks and Caucasians. The study found that African-Americans were more likely
to have higher mitotic activity in comparison to their Caucasian counterparts. Increased mitotic
activity is associated with elevated levels of estrogen. Estrogen stimulates ductal epithelium and
therefore increases the mitotic activity of the cells. This potentially suggests that AfricanAmerican women may have higher levels of estrogen which could explain their higher mitotic
activity; however, no studies have been conducted at this time to evaluate this difference (Chen
et al., 1994).
African-American women are more likely to be diagnosed with breast cancer at a
younger age than any other ethnicity. Several studies have shown that triple negative breast
cancer has a higher prevalence among premenopausal African-American women (Ismail-Khan &
Bui, 2010; Yamamoto & Iwase, 2010). By the time of diagnosis their cancer is already in the
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later stages of the disease. This makes it difficult to offer many treatment options for these
patients (C. K. Anders & Carey, 2009; Reis‐Filho & Tutt, 2008; Stockmans, Deraedt, Wildiers,
Moerman, & Paridaens, 2008). Previously it was shown that 54% of tumors in AfricanAmerican women lack the estrogen and progesterone receptors. This causes them to be more
vulnerable to lymphatic invasion and necrosis (Jones et al., 2004). Other factors that may play a
role in the poor prognosis are genetic mutations and molecular alterations such as the presence of
the BRCA1 gene. The BRCA1 gene causes patients to be more susceptible to breast cancer. The
cause for this disparity is not fully understood at this time. Germline mutations of the BRCA1
tumor-suppressor gene are triple negative. These breast tumors are typically basal nature. The
BRCA1 gene plays a role in DNA repair, transcriptional regulation, and cell cycle check point
control (C. Anders & Carey, 2008).
2.4 Breast Cancer Therapeutic Options
Options for breast cancer treatment vary depending on the staging of the disease as well
as taking in account the patient’s age. The goal is to treat the disease while preserving the quality
of life of the patient. Options include surgery, radiation, hormone therapy, chemotherapy, and
target therapy. The goal of surgery is to remove the cancer from the breast. This is also seen as a
method to evaluate the stage of the disease. Patients have the option to receive either a
lumpectomy or a mastectomy. Lumpectomies only remove cancerous tissue from the breast,
while mastectomies are the complete removal of the breast (Veronesi et al., 2002). Radiation can
be given either externally or internally. External beam radiation is given over a course of 6
weeks. Internal radiation is also known as brachytherapy. Brachytherapy uses radiation seeds
sent to the localized area of the disease to directly target the cancer (Beitsch, Shaitelman, &
Vicini, 2011).
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Systemic therapy uses anti-cancer drugs, which can be administered via injection or
orally. This allows the medication to enter the bloodstream and flow throughout all parts of the
body. This form of therapy includes three components: targeted therapy, chemotherapy, and
hormone therapy. Each component has a different mechanism allowing it to be more effective
than another depending on the staging of the disease. Targeted therapy focuses on attacking
specific parts of cancer cells, chemotherapy attacks cancer cells, and hormone therapy works to
block the natural hormones of the body such as estrogen (Mauri, Pavlidis, & Ioannidis, 2005).
While these drugs and treatments are sometimes very effective they do not always preserve the
quality of life for the patient. Researchers are beginning to examine other treatment options
which may increase the quality of life for patients.
2.5 Cancer and Natural Therapeutics
Due to the adverse side effects associated with conventional therapeutic options, it is
beneficial to examine alternative methods of treatment to assist in preserving the patients’ quality
of life. The use of plants as a cancer therapeutic has a long history, by playing an important role
in anti-cancer agents. Over 60% of anti-cancer agents were derived from natural sources such as
plants, marine organisms and micro-organisms (Cragg & Newman, 2005). Anti-cancer drugs
such as Paclitaxel and Doxorubicin are synthesized from natural products. Paclitaxel is derived
from the taxol extracts of the English yew tree, Taxus. This therapeutic is currently used to treat
ovarian, breast and other cancers. Paclitaxel functions by promoting tubulin assembly and
inhibiting cell proliferation. Doxorubicin, an anthracyclin antibiotic, damages DNA by
intercalation. This therapeutic is derived from the bacteria Streptomyces peucetius (Reddy et al.,
2003).
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It is believed that oxidative damage to DNA plays a role in the formation of cancer. Cells
that divide with damaged DNA, lead to genetic alterations leading to the beginning phases of
cancer. The mechanism of antioxidants found in fruits and vegetables appear to be beneficial in
the earlier stages of cancer (Reddy et al., 2003). The complete mechanism causing this effect is
unknown; however, previously it has been shown that antioxidants can lower the incidence in
several forms of cancer. The active ingredient α- and β-carotene found in carrots has shown
inhibition of pancreatic, colon, and breast cancer by enhancing the chemotaxis ability of
macrophages (Cheng, Shen, Fei Pang, & Chen, 2001).
The lycopene of tomatoes are associated with a lower risk of cancers such as lung,
stomach and prostate cancer. There is a suggestion that this effect may be seen in cervical, breast
and oral cancer as well. As a carotenoid, lycopene has not proven to offer a direct benefit on its
own however it is believed that other compounds found in the tomatoes may interact with
lycopene. It is believed that lycopene functions by limiting cellular macromolecule damage from
reactive oxygen species; however, other mechanisms are possible. Knowledge relating the
properties of lycopene are poorly understood on a pharmacological view (Giovannucci, 1999).
While the mechanism related to the protective effects of antioxidants are not fully understood is
appears that antioxidants have the ability to reduce genetic instability in cancer cells (Reddy et
al., 2003).
2.6 Rosehip Extracts
Rosehip is the fruit of the rose plant that ranges in color from red to orange; however,
there are some species whose color ranges from dark purple to black. Rosehip extracts have been
used as chemopreventive agents due to their mechanistic actions on cancer cells. The elevated
levels of lycopene found in rosehip extracts are associated with increased apoptosis in prostate
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cancer (Amin et al., 2009). Rosehip fruits have shown potent anti-proliferative activity against
colon, breast, and cervical cancer cells in vitro. Rosehips are high in vitamin C (Tumbas et al.,
2011) causing this pseudo fruit to be rich in ascorbic acid, phenolic components, and carotenoids
(Chrubasik et al., 2008). These high antioxidant contents cause rosehips to have high antioxidant
activities. Studies have shown that it is useful in treating arthritis due to its anti-inflammatory
and anti-oxidant effects (Andersson et al., 2011). These dietary antioxidants may contribute to
the protection of biologically important cellular components. Antioxidants function by reacting
with free oxygen radicals and action as reducing agents to induce production of anti-oxidative
enzymes. This contributes to the inhibitory capacity against cell proliferation caused by these
antioxidants (Su et al., 2007). Studies have shown that the Vitamin C and flavonoids found in
rosehips are responsible for the antioxidant activity associated with rosehip products (Wang et
al., 2011). However, it is the polyphenols found within this plant that is responsible for the antiproliferative activity (Wang et al., 2011). The anti-proliferative effects on cell proliferation in
African-American triple negative breast cancer have not yet been tested.
2.7 Phosphatidylinositol 3-Kinase-AKT and Mek/Erk Pathways
Carcinogenesis is a complex multi-step process associated with abnormal proliferation in
an unrestricted manner. This is due to an imbalance between growth promoting and growth
inhibiting mechanisms (HemaIswarya & Doble, 2006). Components of the phosphatidylinositol
3-Kinase-AKT signaling pathway are deregulated in different human cancers. This deregulation
is prevalent in breast cancer and can be seen by the presence of elevated AKT 1 kinase activity,
AKT2 amplification, and overexpression of PI3K and AKT2. The activity of this pathway is
functionally associated with the transformation of viral oncogenes such as the sarcoma viral
oncogene (Src). This pathway is responsible for cellular processes such as cell proliferation,
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growth, apoptosis, and cytoskeletal rearrangement. One component that is deregulated within the
PI3K pathway is the p70 S6 kinase. The p70 S6 kinase regulates the multiple phosphorylation
sites of 40 S ribosomal protein in vivo. The activity of p70 S6 kinase is controlled by multiple
phosphorylation events located within the catalytic, linker and pseudosubstrate domains. This
mitogen is required for cell growth and G1 cell cycle progression (Pullen & Thomas, 1997). The
intracellular catalytic domain of HER-2 receptor can be phosphorylated by the formation of
homodimeric and heterodimeric kinase active-complexes. This then leads to the activation of
signaling pathways, such as PI3K/AKT and MAPK, that promote proliferation or survival of
breast cancer cells (Chang H Song, 2010). The mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K) are two major pathways involved in proliferation and
survival. Mitogens within the MEK/ERK signaling pathway function by transmitting signals
from receptors to regulate gene expression and can also play a role in the prevention of
apoptosis. This pathway interacts with the PI3K pathway to regulate growth in forms of
tumorigenesis (McCubrey et al., 2006). AKT, p70 S6 kinase, and ribosomal protein s6 are
among the most important of the downstream molecules found in these pathways (Chang H
Song, 2010). By understanding the effect that rosehip extracts have on this mitogen it is possible
to explore the usefulness of this extracts as a potential alternative treatment option for aggressive
breast cancers such as triple negative breast cancer.
2.8 Research Objectives
The objective of this thesis was to investigate the effects of crude rosehip extracts on cell
proliferation in African-American breast cancer cell lines, and to identify the signaling pathways
responsible for those effects. It was hypothesized that crude rosehip extracts inhibit cell
proliferation and cell migration in triple negative breast cancer cells at appropriate concentration
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levels by blocking the AKT and Mek/Erk1/2 signaling pathways. Previous studies have shown
that rosehips possess a large amount of phytochemicals which have the ability to prevent cell
proliferation in breast (MCF-7), colon (HT-29) and cervical cancer cell lines (Olsson,
Gustavsson, Andersson, Nilsson, & Duan, 2004; Su et al., 2007; Tumbas et al., 2011). It is
suggested that the anti-cancer effects of rosehip extracts are related to the antioxidant and antiproliferative nature of the extracts (Olsson et al., 2004; Tumbas et al., 2011). Another study
being conducted in our laboratory demonstrated that rosehip extracts are able to prevent cell
proliferation in glioblastoma cells by decreasing phosphorylation in AKT and MAPK signaling
(Cagle et al., 2012). Based on this knowledge this study was designed to examine the effects in
breast cancer cell lines.
The work within this thesis had the following objectives: 1) determine the effect of
rosehip extracts on cell proliferation in African-American breast cancer cell lines; 2) identify
signaling pathways responsible for mediating rosehip extract effects on cell proliferation in
African-American breast cancer cell lines; 3) Examine whether the efficacy of Doxorubicin, a
known breast cancer chemotherapeutic, is increased when cells are pre-treated with rosehip
extracts. There is limited knowledge associated with the effects of rosehip extracts in AfricanAmerican breast cancer cell lines. This thesis investigated the physiological and molecular
mechanisms associated with the effect of rosehip extracts to assist in understanding the
functional role of these extracts, potentially leading to a homeopathic therapeutic option for
aggressive breast cancer subtypes.
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CHAPTER 3
Methodology
3.1 Breast Cancer Cell Lines
Human luminal breast cancer cell lines (LBC): HCC1500, HCC70 and the triple negative
breast cancer (TNBC): HCC1806, MB157 were acquired from the American Type Culture
Collection (ATCC) (Table 3.1). HCC70 is a luminal A breast cancer cell line isolated from a 49
year old African-American woman. This poorly differentiated epithelial cell line overexpresses
p53 oncogene but does not express Her2-neu oncogene; and is positive for estrogen receptor
(ER) but negative for the progesterone receptor (PR). This cell line was established from a
primary, stage IIIA, grade 3, invasive ductal carcinoma with lymph node metastasis. HCC1500
is a luminal A cell line from a 32 year old African-American woman with a stage IIB, grade 2
invasive ductal carcinoma tumor. Established in 1995, this cell line doesn’t express Her2-neu but
expresses p53 oncogene. This patient had a family history of early-onset colon cancer and had a
sister with breast cancer.
HCC1806 is a triple negative breast cancer cell line isolated from a sixty year old
African-American woman. The woman had no family history of breast cancer. This cell line is
negative for estrogen receptor, progesterone receptor, and human epithelial receptor-2. The
tumor that these cells were derived from was stage IIB. The triple negative breast cancer cell line
MB157 was isolated from a 48 year African-American woman with metastatic medullary breast
cancer.
The primary cell line AG11132 was established in 1978 during a breast reduction
mammoplasty from a sixteen year old African-American female. The cell line is used as a model
of non-cancerous breast tissues throughout the study.
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Table 3.1
Characteristics of Triple Negative and Luminal Breast Cancer Cell Lines
Human
Estrogen
Cell Line

Receptor
Status

Progesterone

Her2/neu
Epithelial

p53 oncogene

Receptor-

Status

Receptor

oncogene

Status

Subtype

Status
2 Status

HCC70

Positive

Negative

Negative

Positive/

Negative

Overexpression
HCC1500

Positive

Positive

Negative

Positive

Luminal
A

Negative

Luminal
A

HCC1806

Negative

Negative

Negative

Negative

Negative

TNBC

MB157

Negative

Negative

Negative

Negative

Negative

TNBC

3.2 Breast Cancer Cell Culture Conditions
Breast cancer cell lines were incubated at 37°C in 5% CO 2. The cell lines (HCC70,
HCC1500, and HCC1806) were grown in RPMI media supplemented with 10% Fetal Bovine
Serum (FBS) and penicillin-streptomycin (100unit/µl). MB157 were grown in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% FBS and penicillin-streptomycin.
AG11132 were grown in Mammary Epithelial Cell Growth Medium (MEGM) (Lonza,
Switzerland) without serum. Upon confluency, each cell line was passed with TrypLE Express
(Gibco, New York). Each cell line was passed for 30 passages before a new aliquot was thawed
and
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3.3 Plant Material and Preparation of Crude Extracts
Dried Rosehip calyces and crude Rosehip extracts were a kind gift from Dr. Ipek
Goktepe (North Carolina A&T State University). Freeze dried calyces were grounded to powder.
After grinding, powdered material will be kept in a -20°C freezer until further use. The Rosehip
powder was soaked in 10% deionized water, 80% ethanol (1:5 w/v) or 80% methanol (1:5 w/v)
and sonicated for 20 minutes with continual nitrogen gas purging. Extracts were filtered through
Whatman No. 2 filter paper and evaporated to dryness under reduced pressure. The Rosehip
extracts were stored at -20ºC. The rosehip extracts appear reddish-orange at the end of the
process. The residues of the crude extracts were tested in human breast cancer cell lines for
cellular anti-proliferative activity.
3.4 Colorimetric Cell Proliferation Rate and Viability (MTT) Assay
In order to test the rate of cell proliferation MTT assays were performed. Prior to
treatment 10,000 cells were plated per well in a 96 well plate and allowed to reach 70-80%
confluency overnight. Treatments were prepared by reconstituting the rosehip extracts in m
RPMI or DMEM media plus serum.. Cells were treated with various concentrations of rosehip
extract (1mg/ml, 250ug/ml, 25 ug/ml and 25 ng/ml) for 48 hours in medium (RPMI plus 10%
FBS.) Cells were also treated with U0126 (MEK1/2 inhibitor, Cell Signal: Massachusetts) and
LY294002 (PI3 Kinase inhibitor, Cell Signal: Massachusetts). Wells without cells were given
rosehip treatments to be used as a background.

Following treatment, 0.01mL of 3-(4,5-

dimethylthiazol-2yl)-2,5-diphenyl tetrasodium bromide (MTT) plus PBS, pH of 7.4 was added to
each well. Wells were incubated at 37°C in 5% CO2 for 4 hours in order for MTT cleavage to
occur. Isopropanol (0.1mL) with 0.4 N HCL was then added and mixed thoroughly to aid in
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absorbance measurement. After 1 hour, growth was measured through absorbance measurement
with an ELISA plate reader at two wavelengths of 570nm and 630nm.
3.5 Western Blot Analysis
Cells in a 6 well plate were exposed to varying rosehip concentrations(1mg/ml,
250µg/ml, 25µg/ml and 25ng/ml) for 48 hours. Cell lysates of the exposed cultureswere
extracted with 1% Triton X-100 and 0.2% Nonident P-40 in the presence of protease cocktail
inhibitors. Lysates containing proteins were then separated by SDS-PAGE using 10%
polyacrylamide gels. Proteins were then transferred to Polyvinylidene Fluoride (PVDF)
membrane and blocked in 5% milk in TBS-T for one hour. The PVDF membrane was incubated
with primary antibody overnight at 4°C while shaking. The primary antibody was specific for
phospho-p70 S6 kinase, total p70 S6, phospho-p90RSK, phospho-Akt, total Akt, phosphorp44/42 MAPK (Erk1/2), and phospho-S6 (Cell Signal: Massachusetts). Rab11 and β-tubulin
were used as loading controls. The antibodies were diluted in 5% milk in TBS-T, phosphop90RSK, phosphor-Akt, phospho-p44/42 MAPK (Erk1/2), phospho-S6 ribosomal protein, Rab11
at 1:200; Total Akt at 1:1000, total p70 S6 at 1:1000, and phospho-p70 S6 kinase at 1:1000. βtubulin was diluted in 5% milk in PBS containing Tween 20 at 1:5000 dilution. Membranes were
then washed in TBS-T three times for 10 minutes. The membrane was incubated with secondary
antibody, anti-rabbit, diluted in 5% TBS-T for one hour. The membrane was washed three times
for 10 minutes in TBS-T (washed in PBS containing Tween 20 when probed for β-tubulin).
Electrochemiluminescence (ECL) (Thermo Fisher Scientific: Illinois) substrate was then applied
before wrapping the membrane in transparent plastic wrap and exposed to x-ray film. The x-ray
film was developed to evaluate protein bands.
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3.6 Statistical Analysis
Statistical analysis was conducted on experiments examining cell proliferation using cell
proliferation assays. Experiments were averaged and means and standard deviation from three
individual experiments were analyzed for statistical significance (P <0.001) using a one-tailed
Analysis of Variance (ANOVA) and the Newman-Kuels multiple comparison post-test. Bars
labeled with the same letter are not statistically different (p>0.001).

25
CHAPTER 4
Results
The goal of this research was to investigate the effects of crude rosehip extracts on
African-American Breast Cancer cell lines and investigate the cell signaling pathways associated
with these effects. The study compared the effect of crude rosehip extracts (rosehip methanol,
rosehip ethanol, and rosehip water) in African-American triple negative breast cancer cell lines
(HCC1806 and MB157) and luminal breast cancer cell lines (HCC70 and HCC1500). The
primary tissue (AG11132) was used as a model of non-cancerous breast tissue. Previous studies
have shown that rosehip extracts decrease proliferation in various types of cancer (Cagle et al.,
2012; Fujii & Saito, 2009), however the effect on breast cancer, specifically, triple negative
breast cancer has not yet been studied. Therefore, we hypothesized that crude rosehip extracts
will decrease the cell proliferation in African-American breast cancer cell lines.
4.1 Crude Rosehip Extracts Decrease Cell Proliferation in Breast Cancer Cell Lines
In this set of experiments, the effect of crude rosehip extracts on the proliferation of
breast cancer cells was examined using MTT assays in five cell lines (HCC70, HCC1500,
HCC1806, MB157 and AG1132). Cells were treated for 48 hours with the following controls:
serum starved, plus serum and known cell proliferation inhibitors LY294002 (blocks the AKT
signaling pathway) and U0126 (blocks the MAPK signaling pathway). Each of the breast cancer
cell lines were assayed following treatment with vary concentrations of rosehip extracts
(1mg/ml, 250µg/ml, 25µg/ml and 25ng/ml). Rosehip extracts were prepared in methanol,
ethanol, or water in an effort to determine which extraction method produced more effective
extracts.

26
The initial studies of this objective examined the effect of rosehip water extracts. These
extracts were isolated using 10% deionized water. The MTT (pale yellow substrate) reaction
cleaves living cells to display a dark blue product. This process is a result of cells having active
mitochondria which allows for the cleaving of significant amounts of MTT. The assay can be
used to determine proliferation or complement-mediated cytotoxicity. .Following rosehip water
treatment MTT assays were conducted to observe the relative rate of proliferation. The serum
starved control was a control measure for the non-growth stimulation, and was seen to yield the
lowest rate of cell proliferation. Experimental data is a representation of three experiments (n=3).
The means and standard deviation of the experiments were analyzed for statistical significance
(p<0.001) using a one-tailed analysis of variance and the Newman-Keuls multiple comparison
post-test. Each sample was compared to plus serum. Samples that were statistically different
(p<0.001) were labeled B. Samples that were not statistically different from the plus serum
control (p>0.001) were labeled A. The results are displayed in Figure 4.1. In the HCC70 cell
line (Figure 4.1 A); in comparison to the plus serum positive control there was a significant
decrease in cell proliferation. The concentrations showed a dose-dependent decrease in cell
proliferation. In the HCC1500 cell line (Figure 4.1 B), in comparison to the plus serum positive
control there was a significant (p<0.001) decrease in cell proliferation at the highest
concentration of rosehip water. The highest concentration of rosehip water yielded a lower cell
proliferation rate in comparison to the two known cell proliferation inhibitors (LY294002, 20µM
and U0126 10µM).
The triple negative breast cancer cell line HCC1806 (Figure 4.1 C) showed a significant
decrease in cell proliferation at all concentration levels of rosehip water. On the other hand
MB157, another triple negative breast cancer cell line (Figure 4.1 D), showed a decrease in
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proliferation; however, there was no statistical significance (p>0.001). The inhibitors LY294002
(20µM) showed a greater decrease in cell proliferation than the varying concentrations of rosehip
water.

Figure 4.1 Effect of Rosehip Water on Breast Cancer Cell Lines.
The second phase of objective1 examines the effect of rosehip ethanol extracts in the
breast cancer cell lines (Figure 4.2). In the HCC70 cell line (Figure 4.2 A), in comparison to the
plus serum control rosehip ethanol at the two higher concentrations (1mg/ml and 250µg/ml)
decreased cell proliferation. The highest concentration significantly decreased (p<0.001) the rate
of cell proliferation better than the two known cell proliferation inhibitors. In the HCC1500 cell
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line (Figure 4.2 B), the highest concentration of rosehip ethanol had the greatest effect in
decreasing cell proliferation. The triple negative breast cancer cell lines HCC1806 and MB157
(Figure 4.2 C & D respectively) showed a significant decrease (p<0.001) of cell proliferation at
all concentrations of rosehip ethanol.

Figure 4.2 Effect of Rosehip Ethanol on Breast Cancer Cell Lines.
The third phase of this objective examines the effect of Rosehip methanol in the breast
cancer cell lines. In the luminal breast cancer cell lines HCC70 (Figure 4.3 A) and HCC1500
(Figure 4.3 B), in comparison to the plus serum control rosehip methanol significantly decreased
(p<0.001) the rate of cell proliferation in dose-dependent manner with the greatest effect being
seen in the highest concentration. In the triple negative breast cancer cell line HCC1806 (Figure
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4.3 C), in comparison to the plus serum control rosehip methanol extracts significantly decreased
(p<0.001) the rate of cell proliferation in a dose-dependent manner with the highest
concentration presenting a cell proliferation rate lower than the minus serum control. In the
MB157 cell line (Figure 4.3 D); in comparison to the plus serum control all concentrations of
rosehip methanol decreased the rate of cell proliferation. These concentrations decreased the rate
of proliferation to a rate lower than the minus serum control and the two known inhibitors. This
suggests a potentially toxic effect of the rosehip extracts in the breast cancer cell lines.

Figure 4.3 The Effect of Rosehip Methanol Extracts on Breast Cancer Cell Lines.
The final phase of objective one examined the effect of rosehip extracts sonicated in the
presence of methanol. Rosehip methanol extracts demonstrated a significant decrease (p<0.001)
in each of the breast cancer cell lines at each of the varying concentrations. In the luminal breast
cancer cell lines and the HCC1806 triple negative breast cancer cell line the rosehip extractmediated decrease occurred in a dose-dependent manner. In order to determine whether rosehip
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extracts were detrimental to normal breast cells, treatments were administered to the AG11132
primary cell line to determine the effect on cell proliferation rate (Figure 4.4). In this preliminary
experiment, the effect of rosehip methanol extracts was examined to give a model of noncancerous breast tissue. The rosehip methanol extracts significantly decreased (p<0.001) the rate
of cell proliferation in the three higher concentrations (1mg/ml, 250µg/ml and 25µg/ml). The
two higher concentrations caused a decrease in proliferation lower than the two known cell
proliferation inhibitors.

Figure 4.4 Effect of Rosehip Methanol on AG11132 Primary Cell Line.
4.2. Rosehip Extracts Induce Apoptosis in HCC1500 Breast Cancer Cell line at the Higher
Concentrations
Previously it has been shown that rosehip extracts decrease cell proliferation without
inducing apoptosis in glioblastomas (Cagle et al., 2012). In order to determine if the rosehip
methanol extracts induced apoptosis in the breast cancer cell lines western blot analysis was
conducted to examine the amount of poly(ADP-ribose) polymerase (PARP) cleavage expression.
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PARP is a critical component within cell signaling which is responsible for post-translational
modifications of proteins. This occurs are a response to various different agents. PARP is
important for regulation cellular processes such as DNA repair, cell death, and chromatin
functions or genomic stability. There are large amounts of PARP found in the nucleus. When
PARP becomes cleaved the cell begins to undergo programmed cell death known as apoptosis.
Each cell line was treated with the varying concentration of rosehip methanol (1mg/ml,
250µg/ml, 25µg/ml and 25ng/ml), the minus and plus serum control, the two known cell
proliferation inhibitors LY294002 (20µM) and U0126 (10µM), and Staurosporine (1µM).
Staurosporine is a chemical used to induce apoptosis in cells. Western blot analysis was
conducted on the two luminal breast cancer cell lines (HCC70 and HCC1500) and the triple
negative breast cancer cell line (HCC1806) (Figure 4.5). The results demonstrated that at the two
higher concentrations there was PARP cleavage seen in the HCC1500 cell line. The HCC70 and
HCC1500 cell line did not display any PARP cleavage. The primary cell line AG11132 showed a
decrease in cell proliferation when treated with rosehip methanol extracts (Figure 4.4). Western
blot analysis was conducted to compare rosehip methanol extracts to Staurosporine. The was no
PARP cleavage in any of the rosehip concentrations, suggesting rosehip methanol does not
induce apoptosis (Figure 4.6).
4.3 Rosehip Methanol Extracts Decrease Phosphorylation of the AKT Cell Signaling
Pathway and MAPK Protein
It was previously shown that in glioblastomas rosehip extracts decrease cell proliferation
by inhibiting the MAPK and AKT Pathways (Cagle et al., 2012). In order to determine if these
cell signaling pathways were responsible for the decrease in cell proliferation associated with
rosehip methanol treatment, western blot analysis was conducted. Two luminal breast cancer cell
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lines (HCC70 and HCC1500 and one triple negative breast cancer cell line (HCC1806) were
treated with the varying concentrations of rosehip methanol and known inhibitors of the AKT
and MAPK pathways.

Figure 4.5 Induction of Apoptosis in Breast Cancer Cell lines.

Figure 4.6 Induction of Apoptosis in AG1132 Primary Cell Line.
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AKT is the survival pathway responsible for cellular responses such as cell proliferation, growth,
and apoptosis (Pullen & Thomas, 1997). The MAPK signaling pathways functions by
transmitting signals from receptors to regulate gene expression and can also play a role in the
prevention of apoptosis. This pathway interacts with the PI3K pathway to regulate growth in
forms of tumorigenesis (McCubrey et al., 2006).
In the HCC70 cell line rosehip methanol decreased phosphorylation of AKT in all
concentrations of rosehip methanol (Figure 4.7). When examining the phosphorylation of
p70S6K, which is downstream from AKT, all the concentrations of rosehip methanol decreased
phosphorylation at this level, suggesting that p70S6K may be where rosehip methanol is
targeting. When examining the MAPK cell signaling pathway, rosehip methanol treated cells
showed a decreased in phosphorylation at all concentrations of rosehip methanol (Figure4.7).
In the HCC1500 cell line (Figure 4.8), there was a decrease in phosphorylation of cell
pathway members with the highest concentration of rosehip methanol. Phosphorylation of
p70S6K was decreased at all concentrations of the rosehip methanol. This was confirmed by the
decreased phosphorylation of S6 which is a downstream target of p70S6K. This suggests that
p70S6K may be the targeted protein within this cell signaling pathway. The MAPK signaling
pathway also showed decreased phosphorylation at the two higher concentrations when treated
with rosehip methanol (Figure 4.8). Together these data demonstrate that both the AKT and
MAPK signaling pathways are being regulated following exposure to rosehip extracts. (Figure
4.8)
Data in these figures (Figure 4.7 and 4.8) show that decreases in the phosphorylation
states of key protein kinases (p70s6K and MAPK) correlates with decreases in cell proliferation
observed in HCC70 and HCC1500 cell lines (Figure 4.3 A and Figure 4.3 B).
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Figure 4.7 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK Signaling
in HCC70 Cells.
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Figure 4.8 Inhibitory Effect of Rosehip Methanol Extract Concentration AKT and MAPK
Signaling in HCC1500 Cells.
In the triple negative breast cancer cell line (Figure 4.9) a decrease in phosphorylation
was seen at the highest concentration of rosehip methanol. When examining the phosphorylation
of the S6 protein there was a decrease in phosphorylation in all concentrations in a dosedependent manner. As the concentrations of rosehip methanol decreased the phosphorylation of
the S6 protein increased. The data shows a correlation with the decrease in cell proliferation
observed in HCC1806 cell lines (Figure 4.3 C).
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Figure 4.9 Inhibitory Effect of Rosehip Methanol Extract Concentration on AKT and MAPK
Signaling in HCC1806 Cells.
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In a preliminary attempt to examine the effect of rosehip methanol extracts on the
molecular signaling of the primary cell line AG11132 western blot analysis was conducted as
well. At the highest concentration of rosehip methanol there was an increase in the
phosphorylation of AKT (Figure 4.10). There was a decrease in proliferation seen when these
cells were treated with rosehip methanol (Figure 4.4). This suggests that while cell proliferation
is being decreased following treatment with rosehip methanol extracts the cells are switching on
their survival mechanism in an attempt to survive the effects of the treatment.

Figure 4.10 Rosehip Methanol Extracts Increase the Phosphorylation of AKT Protein in
AG11132 Cells.
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4.4 Rosehip Extracts Have a Potential Synergistic Effect in Cell Lines Lacking the
Progesterone Receptor
In an attempt to better understand the potential of rosehip extracts as a homeopathic
remedy against breast cancer cell lines, experiments were designed to determine whether the
anti-proliferative capacity of rosehip extracts compared to that of Doxorubicin. The first part of
this objective was to determine which concentration would best work with the breast cancer cell
lines (HCC70, HCC1500, and HCC1806) within this study. Previous studies have used
Doxorubicin at concentrations such as 1µM, 5µM and 10µM for 24 hours in 4T1 breast cancer
cell line. (Du et al., 2010). Based on these studies we examined those concentrations to
determine which would give the best effect in the two luminal breast cancer cell lines (HCC70
and HCC1500) and the triple negative breast cancer cell line (HCC1806) (Figure 4.11). In this
preliminary study, the two luminal breast cancer cell lines Doxorubin at a 5µM concentration
showed a greater decrease in cell proliferation in comparison to the plus serum control (Figure
4.11 A & B). However in the triple negative breast cancer cell line HCC1806 the greatest
decrease in cell proliferation was yielded at the 10µM concentration of Doxorubin (Figure 4.11
C). Based on these findings we decided to increase the concentration to 20µM in order to
examine the effects of doxorubicin when combined with rosehip methanol.
Studies are beginning to combing the use of herbs and plant extracts with conventional
drugs for several reasons. Presently the cost of health care, drug prices and the number of
patients are constantly increasing which play a role in the increasing interest in developing
phytomedicines that can be combined with current therapeutics (HemaIswarya & Doble, 2006).
Previously studies have shown that natural products such as curcumin have a synergistic effect
when combined with Doxorubicin (HemaIswarya & Doble, 2006; Notarbartolo et al., 2005). This
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Figure 4.11 Effect of Doxorubicin on Breast Cancer Cell Lines.
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knowledge was the basis of the design for the second part of this objective. In this preliminary
study breast cancer cell lines (HCC70, HCC1500 and HCC1806) were exposed to the following
treatments: 1) 1mg/ml rosehip methanol (48 hours), 2) 20µM Doxorubicin (48 hours), 3)
pretreated with 1mg/ml Rosehip Methanol (24 hours) and then treated with 20µM Doxorubicin
(24 hours), 4) Treated with 1mg/ml Rosehip Methanol and 20µM Doxorubicin simultaneously
(48hours).

Figure 4.12 Effect of Rosehip Methanol Versus Doxorubicin.
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The minus serum control yielded the lowest rate of proliferation therefore each treatment was set
relative to this. Each cell line responded differently to the specific treatments. In the HCC70 cell
line (Figure 4.12 A); the lowest yield in cell proliferation rate was when the cells were pretreated
with the 1mg/ml rosehip methanol. In the HCC1500 cell line (Figure 4.12 B), the 1mg/ml
rosehip methanol treatment presented the lowest yield. In the triple negative breast cancer cell
line, HCC1806, (Figure 4.12 C) there were similar yields with the 1mg/ml rosehip methanol
treatment and the pretreatment option. Both of these treatments presented the lowest yield in
comparison to the plus serum control.
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CHAPTER 5
Discussion and Future Research
Triple negative breast cancer is associated with an aggressive nature due to their lack of
specific receptors. Due to this problem it is imperative that effective preventive and therapeutic
ventures be explored with this disease (Irvin Jr & Carey, 2008). The objective of this thesis was
to investigate the effects of crude rosehip extracts on cell proliferation in African-American
breast cancer cell lines, and to identify the signaling pathways responsible for those effects. It
was hypothesized that crude rosehip extracts inhibit cell proliferation and cell migration in triple
negative breast cancer cells at appropriate concentration levels by blocking the AKT and
Mek/Erk1/2 signaling pathways. Previous studies have shown that rosehips possess a large
amount of phytochemicals which have the ability to prevent cell proliferation in breast (MCF-7),
colon (HT-29) and cervical cancer cell lines (Olsson et al., 2004; Su et al., 2007; Tumbas et al.,
2011). It is suggested that the anti-cancer effects of rosehip extracts are related to the antioxidant
and anti-proliferative nature of the extracts (Olsson et al., 2004; Tumbas et al., 2011). Another
study demonstrated that rosehip extracts are able to prevent cell proliferation in glioblastoma
cells by decreasing phosphorylation in AKT and MAPK signaling (Cagle et al., 2012). Based
on this knowledge this study was designed to examine the effects in breast cancer cell lines.
5.1 Determined the Effect of Crude Rosehip Extracts on Breast Cancer Cell Line
Proliferation
The first specific aim set out to determine the effect of crude rosehip extracts on luminal
breast cancer cell lines, triple negative breast cancer cell lines, and a primary breast cell line. The
study was able to identify that all extraction methods of rosehip (rosehip water, rosehip ethanol,
and rosehip methanol) were able to decrease the cell proliferation rate at the highest
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concentrations (1mg/ml). Further investigation showed that this effect occurs without toxicity
and inducing apoptosis in breast cancer cell lines. In the primary cell line there was also a
decrease in cell proliferation when treated with rosehip methanol. These results were similar to
those presented in a study which examined the effect of rosehip extracts on glioblastomas (Cagle
et al., 2012)
5.2 Determined Signaling Pathways Effected in Breast Cancer Cell Lines by Crude
Roseship Methanol Extracts
Previous studies demonstrated that the decrease of cellular proliferation in glioblastomas
was associated with a decrease in phosphorylation along the MAPK and AKT cell signaling
pathways (Cagle et al., 2012). The study was able to determine the AKT pathway was regulated
by treatment with rosehip methanol extracts in the luminal and triple negative breast cancer cell
lines. It was suggested in the data that rosehip methanol may target the p70S6K phosphorylation
more specifically. However, it was seen that the primary cell line AG11132 displayed an
increase in AKT phosphorylation suggesting that while cell proliferation is decreased when
treated with rosehip methanol, the survival pathway associated with AKT may be in effect in this
cell line. Further study of the signaling pathways in the primary cell line can assist in explaining
the difference that is observed.
5.3 Determined a Potential Synergistic Effect with Doxorubicin and Rosehip Methanol
Extracts in Breast Cancer Cell Lines Lacking the Progesterone Receptor
Previous studies have shown that natural products such as curcumin have a synergistic
effect when combined with doxorubicin (HemaIswarya & Doble, 2006). Based on this
knowledge this study was able to determine that rosehip methanol may have a potential
synergistic effect with doxorubicin. However, the synergistic effect differs between the cell lines,

44
suggesting that the subtype of cancer will play a critical role in determining the efficacy of this
extract as a potential therapeutic. In this preliminary study, there is a suggested potential
synergistic effect in breast cancer cell lines lacking the progesterone receptor (HCC70 and
HCC1806) (Table 5.1).
Table 5.1
Potential Synergistic Effect of Doxorubicin and Rosehip Methanol
Characteristics

HCC70

Estrogen

Progesterone

Human

Least amount

Receptor

Receptor

Epithelial

of Cell

Status

Status

Receptor-2

Proliferation

Status

after 48 Hrs

Negative

1mg/ml RHM

Non-Triple

+ 20µM

Negative

Positive

Negative

Subtype

Doxorubicin
HCC1500

Positive

Positive

Negative

1mg/ml RHM

Non-Triple
Negative

HCC1806

Negative

Negative

Negative

1mg/ml RHM,
1mg/ml RHM
+ 20µM
Doxorubicin

TNBC
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5.4 Future Directions
The present studies indicate rosehip extracts have the capacity to decrease cell
proliferation in African-American breast cancer cell lines. In cell lines lacking the progesterone
receptor this effect occurs without promoting apoptosis. The decrease in cell proliferation is
associated with decreased phosphorylation of proteins within the AKT and MAPK signaling.
This data suggests an anti-proliferative role for rosehip extracts in breast cancer cells. This data
suggests that rosehip extracts have the potential to serve as a therapeutic option for difficult to
treat breast cancers. In order to expand the knowledge, gained from these studies experiments
will be designed to assist in determining cell signaling pathways associated with the decreased
cell proliferation rates of the triple negative breast cancer cell line MB157. The preliminary data
suggested a potential synergistic effect of Doxorubicin and 1mg/ml rosehip methanol extracts.
Future studies will examine the role that the progesterone plays in mediating this potential
synergistic effect. The study will also incorporate the MB157 cell line in order to determine if
there is a similar trend in the findings related to the progesterone receptor. While this study
focused on the rosehip methanol extracts, future studies will examine if there is a molecular
difference between the rosehip ethanol and rosehip water extracts. Investigation of these
differences will assist in taking steps towards determining the active ingredient within the
rosehip extracts. These extracts will also be used to continue the tests of doxorubicin efficacy.
The potential future studies would examine whether Doxorubicin efficacy is increased when pretreated with the rosehip ethanol and rosehip water extracts. The end results of this study will
broaden the knowledge of these extracts and how they regulate breast cancer cell proliferation.
The knowledge obtained from this and future studies will all for the efficacy of rosehip extracts
as a potential homeopathic therapeutic option for aggressive breast cancer subtypes.
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Appendix A:
Relative Densitometry Values of Protein Expression

Figure A.1 Relative Densitometry Values of HCC1806 AKT Protein
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Figure A.2 Relative Densitometry Values of HCC1806 p70S6K Protein
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Figure A.3 Relative Densitometry Values of HCC1806 S6 Protein
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Figure A.4 Relative Densitometry Values for HCC1806 MAPK Protein
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Figure A.5 Relative Densitometry Values for HCC1500 AKT Protein
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Figure A.6 Relative Densitometry Values for HCC1500 p70S6K Protein
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Figure A.7 Relative Densitometry Values for HCC1500 S6 Protein
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Figure A.8 Relative Densitometry Values for HCC1500 MAPK Protein

62

Figure A.9 Relative Densitometry Values for HCC70 AKT Protein
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Figure A.10 Relative Densitometry Values for HCC70 p70S6K Protein
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Figure A.11 Relative Densitometry Values for HCC70 S6 Protein
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Figure A.12 Relative Densitometry Values for HCC70 MAPK Protein
.
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Appendix B:
Figure Legends
Figure 4.1 Effect of Rosehip Water on Breast Cancer Cell Lines Luminal Breast Cancer Cell
Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806, MB157)
were treated with rosehip water extracts, in the presence of 10% FBS for 48 hours at various
concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to rosehip extracts, known
inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and AKT pathway (LY 294002, 20 µM)
were used. Each value is presented as the mean and standard deviation of three independent
experiments. Columns of each graph represent relative values in comparison to serum-starved
cells. Statistical analysis was conducted using a one-tailed analysis of variance (ANOVA) with
the Newman-Keuls post-test. Bars labeled with different letters are significantly different from
one another (P<0.001). Bars labeled with the same letter are not significantly different
(P>0.001). A) HCC70 B) HCC1500 C) HCC1806 and D) MB157

Figure 4.2 Effect of Rosehip Ethanol on Breast Cancer Cell Lines Luminal Breast Cancer
Cell Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806,
MB157) were treated with rosehip ethanol extracts, in the presence of 10% FBS for 48 hours at
various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to rosehip extracts,
known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and AKT pathway (LY 294002,
20 µM) were used. Each value is presented as the mean and standard deviation of three
independent experiments. Columns of each graph represent relative values in comparison to
serum-starved cells. Statistical analysis was conducted using a one-tailed analysis of variance
(ANOVA) with the Newman-Kuels post-test. Bars labeled with different letters are significantly
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different from one another (P<0.001). Bars labeled with the same letter are not significantly
different (P>0.001). A) HCC70 B) HCC1500 C) HCC1806 and D) MB157

Figure 4.3 Effect of Rosehip Methanol on Breast Cancer Cell Lines Luminal Breast Cancer
Cell Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806) were
treated with rosehip methanol extracts, in the presence of 10% FBS for 48 hours at various
concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to rosehip extracts, known
inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and AKT pathway (LY 294002, 20 µM)
were used. Each value is presented as the mean and standard deviation of three independent
experiments. Columns of each graph represent relative values in comparison to serum-starved
cells. Statistical analysis was conducted using a one-tailed analysis of variance (ANOVA) with
the Newman-Kuels post-test. Bars labeled with different letters are significantly different from
one another (P<0.001). Bars labeled with the same letter are not significantly different
(P>0.001). A) HCC70 B) HCC1500 C) HCC1806 and D) MB157

Figure 4.4 Effect of Rosehip Methanol on AG1132 Primary Cell AG11132 Primary cell line
was treated with rosehip methanol extracts, in the presence of 10% FBS for 28 Hours at various
concentration (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to rosehip extracts, known
inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and Akt pathway (LY 294002, 20 µM)
were used. Each value is presented as the mean and standard deviation of three independent
experiments. Columns of each graph represent relative values in comparison to serum-starved
cells. Statistical analysis was conducted using a one-tailed analysis of variance (ANOVA) with
the Newman-Keuls post-test. Bars labeled with different letters are significantly different from
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one another (P<0.001). Bars labeled with the same letter are not significantly different
(P>0.001).

Figure 4.5 Induction of Apoptosis in Breast Cancer Cell Lines Luminal Breast Cancer Cell
Lines (HCC70, HCC1500) and Triple Negative Breast Cancer cell lines (HCC1806) were treated
with rosehip metanol extracts, in the presence of 10% FBS for 48 hours at various concentrations
(1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to rosehip extracts, known inhibitors of the
Erk/MAPK pathway (U-0126, 10 µM) and Akt pathway (LY 294002, 20 µM) were used. Each
cell line was also exposed to Staurosporine (1µM) for 3h (HCC1500) or 8h (HCC70 and
HCC1500) to promote cell death an dPARP cleavage. Cleaved PARP is represented by the lower
band and total PARP is represented by the lower band. A) HCC70 B) HCC1500 and C)
HCC1806

Figure 4.6 Induction of Apoptosis in AG11132 Primary Cell Line AG11132 primary cell line
was treated with rosehip methanol extracts, in the presence of 10% FBS for 48 hours at various
concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to the varying
concentrations of rosehip methanol the cell line was also exposed to Staurosporine (1µM) for
3hto promote cell death an d PARP cleavage. Cleaved PARP is represented by the lower band
and total PARP is represented by the lower band.

Figure 4.7 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK
signaling in HCC70 cells HCC70 cells were treated with rosehip methanol in the presence of
10% FBS for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In
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addition to rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and
AKT pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2),
AKT, p70S6K, and S6 was determined by western blotting analysis. Tubulin was used as a
protein loading control. Densitometry was used to determine the relative values of protein
expression (Appendix)

Figure 4.8 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK
signaling in HCC1500 cells HCC1500 cells were treated with rosehip methanol in the presence
of 10% FBS for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In
addition to rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and
AKT pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2),
AKT, p70S6K, and S6 was determined by western blotting analysis. Tubulin was used as a
protein loading control. Densitometry was used to determine the relative values of protein
expression (Appendix)

Figure 4.9 Inhibitory Effect of Rosehip Methanol Concentration on AKT and MAPK
signaling in HCC1806 cells HCC1806 cells were treated with rosehip methanol in the presence
of 10% FBS for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In
addition to rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and
Akt pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2),
AKT, p70S6K, and S6 was determined by western blotting analysis. Tubulin was used as a
protein loading control. Densitometry was used to determine the relative values of protein
expression (Appendix)
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Figure 4.10 Rosehip Methanol Extracts Increase the Phosphorylation of AKT protein in
AG11132 cells AG11132 cells were treated with rosehip methanol in the presence of 10% FBS
for 48 hours at various concentrations (1mg/ml, 250 µg/ml, 25 µg/ml, 25 ng/ml). In addition to
rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM) and Akt
pathway (LY 294002, 20 µM) were used. The phosphorylation status of MAPK (Erk1/2), AKT,
and S6 was determined by western blotting analysis. Tubulin was used as a protein loading
control. Densitometry was used to determine the relative values of protein expression
(Appendix)

Figure 4.11 Effect of Doxorubicin on Breast Cancer Cell Lines Luminal Breast Cancer Cell
Lines (HCC70, HCC1500) and a Triple Negative Breast Cancer cell line (HCC1806) were
treated with Doxorubicin, in the presence of 10% FBS for 48 hours with various concentrations
of Doxorubicin (10uM, 5µM, 1µM) In addition to Doxorubicin, known inhibitors of the
Erk/MAPK pathway (U-0126, 10 µM) and AKT pathway (LY 294002, 20 µM) were used. A)
HCC70 B) HCC1500 and C) HCC1806
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Figure 4.11 Effect of Rosehip Methanol versus Doxorubicin Luminal Breast Cancer Cell
Lines (HCC70, HCC1500) and a Triple Negative Breast Cancer cell line (HCC1806) were
treated with rosehip methanol extracts and Doxorubicin, in the presence of 10% FBS for 48
hours with various treatments (1mg/ml rosehip methanol, 20uM Doxorubicin, 1mg/ml rosehip
methanol + 20µM Doxorubicin, 24h rosehip methanol, 24hr 20µM Doxorubicin) In addition to
Doxorubicin and rosehip extracts, known inhibitors of the Erk/MAPK pathway (U-0126, 10 µM)
and AKT pathway (LY 294002, 20 µM) were used. A) HCC70 B) HCC1500 and C) HCC1806

